In Vivo Grade Recombinant Human IgG4-S228P Bispecific Isotype Control Antibody

* CHF, excl. 8.1% VAT and shipping costs

Product Description

The ideal recombinant human IgG4 bispecific isotype control antibody (hIgG4 S228P kappa bispecific isotype control) has low or no specific binding to any human sample, and humanized or completely human variable regions in addition to the human IgG4 S228P kappa constant regions. The human IgG4 kappa bispecific isotype control and mutants can be used in the cell-based assay or animal model as the antibody negative control when evaluating fully human, humanized, or chimeric antibodies.The hIgG4 bispecific isotype control mutants were generated because the corresponding mutations had been introduced to some human IgG4 therapeutic antibody candidates. For example, S228P, an engineered mutation in the core hinge region, is used to prevent Fab-arm exchange in vivo of human IgG4 molecules; P329G substitution combined with S228P and L235E was shown to decrease effector functions by disrupting the Fc/Fcγ receptor interface. When clients test their engineered antibody candidates, the silent Fc effctor function human IgG4 isotype controls are useful for in vivo use.Welcome to contact us and ask for a quote for the engineered human IgG4 bispecific isotype control mutants, hIgG4 bispecific isotype control and Fc silenced mutants with Avi-, His-, and Flag-tags, and biotinylated